Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Purchased by Truist Financial Corp

Truist Financial Corp grew its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 0.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 102,622 shares of the biopharmaceutical company’s stock after purchasing an additional 563 shares during the quarter. Truist Financial Corp owned approximately 0.08% of Halozyme Therapeutics worth $3,793,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the business. Parkside Financial Bank & Trust purchased a new stake in shares of Halozyme Therapeutics in the fourth quarter valued at approximately $64,000. Duality Advisers LP increased its stake in shares of Halozyme Therapeutics by 31.0% in the 4th quarter. Duality Advisers LP now owns 52,926 shares of the biopharmaceutical company’s stock worth $1,956,000 after acquiring an additional 12,521 shares during the last quarter. Cetera Trust Company N.A acquired a new stake in shares of Halozyme Therapeutics in the 4th quarter worth $208,000. Handelsbanken Fonder AB raised its holdings in shares of Halozyme Therapeutics by 930.9% during the 4th quarter. Handelsbanken Fonder AB now owns 246,069 shares of the biopharmaceutical company’s stock worth $9,095,000 after acquiring an additional 222,200 shares during the period. Finally, Kornitzer Capital Management Inc. KS boosted its position in shares of Halozyme Therapeutics by 5.1% during the 4th quarter. Kornitzer Capital Management Inc. KS now owns 474,734 shares of the biopharmaceutical company’s stock valued at $17,546,000 after acquiring an additional 23,210 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the company’s stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $41.64, for a total transaction of $416,400.00. Following the sale, the senior vice president now owns 156,558 shares in the company, valued at approximately $6,519,075.12. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Over the last three months, insiders sold 30,000 shares of company stock worth $1,196,800. Company insiders own 2.70% of the company’s stock.

Halozyme Therapeutics Stock Up 2.4 %

Shares of HALO opened at $40.86 on Tuesday. The company’s 50-day simple moving average is $40.01 and its 200-day simple moving average is $37.94. The company has a debt-to-equity ratio of 17.89, a quick ratio of 5.50 and a current ratio of 6.64. Halozyme Therapeutics, Inc. has a 1 year low of $29.85 and a 1 year high of $45.00. The stock has a market capitalization of $5.19 billion, a PE ratio of 19.37, a P/E/G ratio of 0.47 and a beta of 1.26.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). Halozyme Therapeutics had a return on equity of 248.20% and a net margin of 33.96%. The business had revenue of $230.04 million for the quarter, compared to analyst estimates of $235.25 million. Analysts forecast that Halozyme Therapeutics, Inc. will post 3.43 earnings per share for the current fiscal year.

Analysts Set New Price Targets

HALO has been the topic of a number of analyst reports. Benchmark reaffirmed a “buy” rating and set a $50.00 target price on shares of Halozyme Therapeutics in a research note on Tuesday, April 16th. The Goldman Sachs Group cut their target price on Halozyme Therapeutics from $45.00 to $40.00 and set a “neutral” rating for the company in a research note on Thursday, January 18th. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price target on shares of Halozyme Therapeutics in a research note on Tuesday, April 30th. TheStreet downgraded Halozyme Therapeutics from a “b-” rating to a “c+” rating in a research report on Monday, January 22nd. Finally, JMP Securities restated a “market outperform” rating and issued a $72.00 price objective on shares of Halozyme Therapeutics in a report on Wednesday, February 21st. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $53.29.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.